In January 2020, the financial conglomerate Visa announced it was acquiring a relatively unknown startup, Plaid, for $5.3 billion. Corporate acquisitions like these are not uncommon, but someone at the United States Department of Justice took notice of this announcement. Visa had established a stranglehold on financial transactions. The Justice Department moved to stop the acquisition on grounds that Plaid posed “a threat to this monopoly: it has been developing an innovative
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Nectin Therapeutics Raises $25M for Immuno-Oncology Therapies
What You Should Know:
- Nectin Therapeutics Ltd., (Nectin) a biotechnology company developing novel targeted immunotherapies to address resistance to approved immune-oncology treatments, announced it has extended its Series A financing to over $25 million. IBF and Peregrine Ventures led the round, with participation from aMoon Fund and other existing investors.
- The funding will be used to support the ongoing clinical evaluation of NTX1088, and to further advance the company’s pipeline of
Read More
How AI-Based Drug Repurposing Could Help Prevent Repetitive Behavior Disorders
Repetitive behavioral disorders such as obsessive-compulsive disorder (OCD), Tic Disorder and Tourette Syndrome have been challenging to treat because they involve considerable complexity. For example, the symptoms of one disorder can vary among individuals as does the coexistence or non-existence of other behavior disorders such as anxiety and depression. Further, the treatment of OCD, Tic Disorder and Tourette Syndrome varies depending on
Read More
Rgenta Therapeutics Raises $52M for Integrative RNA-Targeting Discovery Platform
What You Should Know:
- Rgenta Therapeutics Inc. raises a $52M Series A round led by AZ-CICC Healthcare Investment Fund with participation from all existing investors and new investors including Korean Investment Partners, Delos Capital.
- Rgenta Therapeutics is focusing on developing RNA-targeting medicines for historically undruggable disease targets.
Targeting the “Undruggables”
Only a quarter of the proteins implicated in human diseases are currently druggable by traditional
Read More
Eyenovia Secures $15M for Ophthalmic Drug Delivery Technologies
What You Should Know:
- Eyenovia, Inc., a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that the company enters a $15M credit facility with the Avenue Venture Opportunities Fund, L.P. (“Avenue Venture Debt Fund” or “Avenue”).
- The financing is
Read More
Summer Health Launches Messaging-Based Pediatric Care to Combat the RSV, Flu, and COVID Tripledemic
What You Should Know:
- Summer Health, the first text-based pediatric care provider designed to offer parents support, prescriptions, and referrals within just 15 minutes, today launched free trials to combat the U.S. tripledemic plagued by the rise of RSV, Flu, and COVID cases amongst children.
- Amid a growing pediatric-care crisis that has caused an overflow in emergency rooms and doctor’s offices across the country, Summer Health aims to help relieve the overwhelming burden and be the
Read More
RSNA: Flywheel Builds Data Platform for Unbiased Breast Imaging AI
What You Should Know:
- Today, at RSNA, Flywheel, a leading data management platform for biomedical research and collaboration announces the creation of a federated data platform for the development of unbiased breast imaging AI.
- Funded in part by the NIH, the federated network will support breast imaging AI research and collaboration—on a scale not previously possible.
Leveraging Flywheel Discovery & Exchange
Two Flywheel technologies underpin the project. Flywheel
Read More
What Has COVID Ever Done For Us? Here 9 Examples
The early 2020s will be studied by historians as a time of global uncertainty when an unknown pathogen caused a public health emergency that brought the world to the brink.
It may also be remembered as a time of unparalleled cooperation and advancement in technologies, prompted by the Covid pandemic, that provided enduring benefits for generations to come.
Just as the two world wars of the 20th Century were the deadliest and most attritional in history, they also triggered developments in
Read More
Site Enablement Platforms Can Accelerate Clinical Trials by 6 Weeks and Reduce Costs by Over $1M
What You Should Know:
- Florence HealthcareTM, a clinical research technology company headquartered in Atlanta, Georgia, recently announced the completion of a year-long third-party study on the impact of Site Enablement PlatformsTM on clinical research timelines and costs.
- The study by Marketcap Consulting is the first to compare how traditional site management approaches differ from site-first Site Enablement Platforms. The study looked at the impact of traditional sponsor
Read More
Haystack Oncology Launches with $56M for Post-Op Cancer Detection Tech
What You Should Know:
- Haystack Oncology ("Haystack"), an oncology company that applies the next generation of circulating tumor DNA (ctDNA) detection technology raises $56M in Series A financing led by Catalio Capital Management ("Catalio"), which co-founded Haystack through its private equity and structured equity investment vehicles. Additional investors include Bruker, Exact Ventures, the venture arm of Exact Sciences and Alexandria Venture
Read More
